IR@PKUHSC  > 北京大学第一临床医学院  > 核医学科
学科主题临床医学
A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Lu, Xia1,2,3; Wang, Rong Fu1
关键词Tumor Angiogenesis Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor Receptor Integrin Alpha(v)Beta(3) Peptide Rgd Peptide Rrl Tumor Molecular Imaging Targeted Therapy
刊名CURRENT PHARMACEUTICAL DESIGN
2012-03-01
18期:8页:1032-1040
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]CYCLIC RGD PEPTIDES ; BINDING PEPTIDES ; CANCER ; INTEGRIN ; PET ; EXPRESSION ; THERAPY ; AGENT ; ALPHA-V-BETA-3 ; CONFORMATION
英文摘要

Angiogenesis is necessary for tumor growth, without which a tumor can not grow beyond a few millimeters in diameter. This review summarizes the current status on the research of peptide Arg-Gly-Asp (RGD) and Arg-Arg-Leu (RRL) as well as its derivatives applied in tumor angiogenesis imaging and targeted therapy with single photon emission tomography (SPECT) and positron emission tomography (PET). Peptide RGD sequence Arg-Gly-Asp targeted and combined to integrin alpha(v)beta(3) which has been overexpressed on tumor endothelial cells and many different tumor cells is a robust site for tumor angiogenesis molecular imaging and targeted therapy. The various derivatives of RGD were focused on optimizing its biological characteristics including affinity, targeting efficacy and pharmacokinetics. The other alternative novel tumor angiogenesis molecular imaging agent is RRL peptide which targeted to tumor derived endothelial cells and then applied to visualize tumor angiogenesis with enhanced ultrasonic imaging, optical imaging and SPECT in animal. These novel peptide agents can have promising applications for tumor angiogenesis imaging and antiangiogenic tumor therapy.

语种英语
WOS记录号WOS:000304445900003
项目编号30870729 ; 81071183 ; 30900374 ; 2006CB705705-1 ; 985-2-056 ; 200800011061
资助机构Natural Science Foundation of China (NSFC) ; National Basic Research Program of China (973 Program) ; National Education Ministry ; Research Fund for the Doctoral Program of Higher Education of China
引用统计
被引频次:10[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54332
专题北京大学第一临床医学院_核医学科
作者单位1.Peking Univ, Hosp 1, Dept Nucl Med, Beijing 100034, Peoples R China
2.Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
3.Beijing Aeroapace Gen Hosp, Radiol Ctr, Beijing 100076, Peoples R China
推荐引用方式
GB/T 7714
Lu, Xia,Wang, Rong Fu. A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging[J]. CURRENT PHARMACEUTICAL DESIGN,2012,18(8):1032-1040.
APA Lu, Xia,&Wang, Rong Fu.(2012).A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging.CURRENT PHARMACEUTICAL DESIGN,18(8),1032-1040.
MLA Lu, Xia,et al."A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging".CURRENT PHARMACEUTICAL DESIGN 18.8(2012):1032-1040.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, Xia]的文章
[Wang, Rong Fu]的文章
百度学术
百度学术中相似的文章
[Lu, Xia]的文章
[Wang, Rong Fu]的文章
必应学术
必应学术中相似的文章
[Lu, Xia]的文章
[Wang, Rong Fu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。